TY - JOUR A2 - 马学雷盟 - 西田，裕子AU - 山田，武人PY - 2019 DA - 2019年11月3日TI - 单克隆抗体治疗多发性骨髓瘤：一个挑战，开发新的目标SP - 6084012 VL - 2019 AB- 多发性骨髓瘤的治疗选择（MM）在过去十年中与新药剂的发展极大地改变，例如蛋白酶体抑制剂（PIs）;硼替佐米和免疫调节药物（各种IMiDs）;沙利度胺，来那度胺显露高疗效和MM患者的总生存期（OS）的改善。然而，尽管有这些进展，大多数患者复发，最终成为难治这些疗法。因此，开发新的，有针对性的免疫治疗已积极推行。近日，新一代督察;卡非佐米和伊克昔佐米，IMID;pomalidomide，组蛋白脱乙酰酶抑制剂（HDADi）;帕比司他和单克隆抗体（MoAbs）; and elotuzumab and daratumumab have emerged, and especially, combination of mAbs plus novel agents has led to dramatic improvements in the outcome of MM patients. The field of immune therapies has been accelerating in the treatment of hematological malignancies and has also taken center stage in MM. This review focuses on an overview of current status of novel MoAb therapy including bispecific T-cell engager (BiTE) antibody (BsAb), antibody-drug conjugate (ADC), and chimeric antigen receptor (CAR) T cells, in relapsed or refractory MM (RRMM). Lastly, investigational novel MoAb-based therapy to overcome immunotherapy resistance in MM is shown. SN - 1687-8450 UR - https://doi.org/10.1155/2019/6084012 DO - 10.1155/2019/6084012 JF - Journal of Oncology PB - Hindawi KW - ER -